HIGHLIGHTS
- who: Johann Guillemot and colleagues from the Institut National de la Santé et de la Recherche Médicale (INSERM), Mont-Saint-Aignan, France, Normandy University, Normandy, France, Rouen University have published the paper: Characterization and Plasma Measurement of the WE-14 Peptide in Patients with Pheochromocytoma, in the Journal: PLOS ONE | www.plosone.org of February/11,/2014
- what: The aim of this study was to investigate the tumoral chromogranin A (CgA)-derived peptide WE-14 and the potential advantage to combine plasma WE-14 detection with the EM66 assay and the existing current CgA . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.